Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum, causing painful ulcers and symptoms such as bloody diarrhea, abdominal pain, and urgent bowel movements. The impact ...

Despite a growing arsenal of advanced therapies for ulcerative colitis (UC), tailoring treatments to individual patients remains a challenge. Might there be a way to refine post-tumor necrosis factor ...

Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer ...

Tumor necrosis factor-α (TNF-α) is a key cytokine involved in the pathogenesis of ulcerative colitis (UC), a chronic inflammatory bowel disease, and has emerged as a promising therapeutic target.

Upadacitinib is now approved for IBD patients unsuitable for TNF blockers after one systemic therapy, broadening treatment options. Clinical trials show upadacitinib's efficacy in achieving remission ...

- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...

Inflammation is the body’s defence system, a way of responding to injury or infection. One key molecule involved in the ...